The city of Cleveland, Ohio, currently has 4 active clinical trials seeking participants for Pancreatic Cancer research studies.
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion
Recruiting
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/12/2025
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Recruiting
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Case Western Reserve University, Cleveland, Ohio +3 locations
Conditions: Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Recruiting
This study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the neoadjuvant setting.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/19/2024
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Recruiting
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mort... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
02/15/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer